Thousands take part in landmark antibody study

Over two and a half thousand people with weakened immune systems have joined the STRAVINSKY study.

Research is exploring if antibody testing can identify who remains at risk of COVID-19 after being vaccinated.

University Hospital Southampton (UHS) is one of the highest recruiting sites. Researchers are now inviting more people to take part before the study closes at the end of the year.

Current recruitment is focused on patients with sickle cell disease, thalassaemia, HIV, Down’s syndrome and heart failure. Recent recipients of a stem cell transplant are also being invited to take part.

STRAVINSKY is co-led by the University of Southampton (UoS) and University of Birmingham. It is funded by the National Institute for Health and Care Research (NIHR) and commissioned by the Department of Health and Social Care.

Still at risk

People who are immunocompromised have a weakened immune system. This affects their ability to fight off infections and diseases. It can also mean COVID-19 vaccines provide less protection.

Around half a million people have a weaker immune system in the UK.

These people may still be at risk of becoming very ill with COVID-19, even after they’ve been vaccinated. The researchers want to find out if antibody testing can identify those most at risk.

Professor Sean Lim is a co-chief investigator for the trial. She is a professor of haematology and translational immunology at UoS and an honorary consultant haemato-oncologist at UHS. Prof Lim said:

“We have identified the groups of people who are more likely to develop severe COVID-19 disease, but each person’s personal risk is more difficult to predict. This study is an important step in shaping future guidance for immunocompromised patients.”

She continued: “The response so far has been fantastic. We are extremely grateful for the support we have received from multiple specialties, including haematology, respiratory, surgery, oncology, neurology, hepatology and the adult congenital cardiac service.

“With recruitment closing at the end of the year, we welcome all patients who are interested to get in touch and help us complete this important research.”

Last chance to take part

The study is closing in on a recruitment target of 3,000 people.

They hope to reach 2,600 people through remote appointments, and another 400 through in-person attendance.

Since recruitment started last autumn, over 2,500 participants have already joined from 11 sites. UHS has recruited 400 participants - the second highest recruiter to the study.

If you would like to be involved, please contact stravinsky@uhs.nhs.uk.